## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity		
Starpharma Holdings Ltd (ASX:SPL)		
ADM		
ABN		
20 078 532 180		

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 \*Class of \*securities issued or to be issued

Share Options

2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued

500,000

Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

As approved at the Annual General Meeting of shareholders on 15 November 2006, the options were issued in accordance with the terms of the company's Employee Share Option Plan and with the following terms and conditions:

Issue price: nil;

Exercise Price: 45.08 cents per share. (Determined on the basis of market value plus 15%. Market value is based on a 15 day volume weighted average price of the Company's shares prior to 1 July 2006, the date of appointment of the Executive to the position of CEO.

Exercise period: From 1st July 2007 to 30 June 2009.

Grant date: 1 July 2006 Expiry date: 30 June 2009

<sup>+</sup> See chapter 19 for defined terms.

Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

Nil

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Employee incentives granted (subject to shareholder approval) to Dr Jacinth K. Fairley on appointment as CEO.

N/A – no existing quoted options

This issue was noted in Appendix 3X – Initial Director's Interest Notice – lodged with ASX on 7 July 2006.

7 Dates of entering \*securities into uncertificated holdings or despatch of certificates

17 November 2006

8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
167,833,986	Ordinary shares

9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

	Number	+Class
)		Options expiring various dates ex various prices (SPLAM):
	220,000 200,000	Exercisable at 93.75 cents and with the following expiry dates: 11 April 2007 30 June 2007
	200,000	Exercisable at 73.00 cents and expiring 31 Dec 2008
		Exercisable at 93.75 cents and with the following expiry dates:
	720,000	8 Feb 2009
	167,000	31 Dec 2009
	100,000	12 May 2010
	300,000	4 July 2010
	100,000	18 July 2010
	1,200,000	Exercisable at 50.13 cents and expiring 6 Oct 2010
	3,207,000	
	500,000	Exercisable at 45.08 cents and expiring 30 Jun 09.

Total prior to this issue:

This issue:

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	

<sup>+</sup> See chapter 19 for defined terms.

13	Ratio in which the +securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has *security holders who will not be sent new issue documents
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements in full through a broker?	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

<sup>+</sup> See chapter 19 for defined terms.

32	How do *security holders disponsible of their entitlements (except by satthrough a broker)?	
33	<sup>+</sup> Despatch date	
	t 3 - Quotation of secued only complete this section if you are	
34	Type of securities (tick one)	
(a)	Securities described in Par	: 1
(b)		end of the escrowed period, partly paid securities that become fully paid, employee tion ends, securities issued on expiry or conversion of convertible securities
Enti	ties that have ticked box 3d	<b>4</b> (a)
Addi	tional securities forming a new	class of securities
Tick to docum	o indicate you are providing the inforents	mation or
35		ity securities, the names of the 20 largest holders of the the number and percentage of additional *securities held by
36	1 1	uity securities, a distribution schedule of the additional umber of holders in the categories
37	A copy of any trust deed for	or the additional +securities

Appendix 3B Page 6 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state: • the date from which they do		
	<ul> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend,</li> </ul>		
	distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 38)	Number	<sup>+</sup> Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.

Appendix 3B Page 8 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before \*quotation of the \*securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == ==

Sign here: Date: 17 November 2006
Company Secretary

Print name:

Ben Rogers

<sup>+</sup> See chapter 19 for defined terms.